Back

Heart rate reduction by selective sinus node blocker (ivabradine) protects against detrimental hemodynamic and structural effects of iv inotrops in heart failure

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Chronic heart failure – Treatment Pharmacotherapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Przemyslaw Leszek

National Institute of Cardiology, Warsaw (Poland)

7 More presentations in this session

Presentation thumbnail
Early commencement of tolvaptan therapy improves clinical outcomes in heart failure patients with preserved function of renal vasopressin V2 receptors
Doctor T. Noto (Sapporo, JP)
Abstract
Presentation thumbnail
Research into the effect of sodium-glucose linked transporter inhibition in left ventricular remodelling in patients with heart failure and diabetes mellitus.
Professor C. Lang (Dundee, GB)
Abstract
Presentation thumbnail
Diminished response to statin therapy predicts future occurrence of heart failure in patients with acute myocardial infarction
Doctor K. Tsuda (Takatsuki, JP)
Abstract
Presentation thumbnail
Titration patterns and clinical characteristics of patients prescribed sacubitril/valsartan in the primary care and cardiology settings in germany
Associate Professor R. Wachter (Leipzig, DE)
Abstract Slides
Presentation thumbnail
Characteristics of heart failure patients treated with Sacubitril - Valsartan in Europe. Results from ARIADNE
Professor U. Zeymer (Ludwigshafen, DE)
Abstract

Access the full session

Session thumbnail
Poster Session 1 - Chronic heart failure – Treatment

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources